Study control, violators, inclusion criteria and defining explanatory and pragmatic trials

被引:55
|
作者
McMahon, AD [1 ]
机构
[1] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland
关键词
randomized controlled trial; pragmatic trial; explanatory trial; inclusion criteria; representativeness; intention to treat;
D O I
10.1002/sim.1120
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Important differences between explanatory and pragmatic studies were originally argued by Schwartz and Lellouch. Three important differences between the two types of study involve study control, study violators and inclusion criteria. It was originally argued that explanatory studies are highly controlled, and pragmatic studies may be looser and more like 'real life'. It was argued that an explanatory study should only analyse those receiving treatment, and a pragmatic study would analyse all randomized patients. Explanatory trials are said to use homogeneous groups, and pragmatic studies have less selection (better generalizability). Some suggestions are put forward to update the original distinctions between these two attitudes for future study design. Poor study control is undesirable (but might be necessary) and should not be welcomed as pragmatic. The intention-to-treat strategy is now considered as standard for nearly all trials. Homogeneity is a red herring for studies in humans. Inclusion criteria should be minimized and they should not be used to justify claims of representativeness. Routine criticism of randomized controlled trials for being unrepresentative is unwarranted. We should accept that most trials in humans are 'explanatory'. The division line should be moved, so that pragmatic studies are in the domain of non-therapeutics and complex treatments. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:1365 / 1376
页数:12
相关论文
共 50 条
  • [31] Inclusion and response criteria for clinical trials in relapsed/refractory acute lymphoblastic leukemia and usefulness of historical control trials
    Goekbuget, Nicola
    Dombret, Herve
    Bassan, Renato
    Wadleigh, Martha
    Doubek, Michael
    Ribera, Josep
    HAEMATOLOGICA, 2017, 102 (03) : E118 - E119
  • [32] Inclusion and exclusion criteria and the problem of describing homogeneity of study populations in clinical trials
    Porzsolt, Franz
    Wiedemann, Felicitas
    Becker, Susanne Isabel
    Rhoads, C. J.
    BMJ EVIDENCE-BASED MEDICINE, 2019, 24 (03) : 92 - 94
  • [33] Pragmatic trials and the ARES study
    Slattery, J
    ALCOHOL AND ALCOHOLISM, 2004, 39 (06): : 477 - 477
  • [34] Exploring the pragmatic and explanatory study design on outcomes of systematic reviews of public health interventions: a case study on obesity prevention trials
    Yoong, Sze Lin
    Wolfenden, Luke
    Clinton-McHarg, Tara
    Waters, Elizabeth
    Pettman, Tahna L.
    Steele, Emily
    Wiggers, John
    JOURNAL OF PUBLIC HEALTH, 2014, 36 (01) : 170 - 176
  • [35] Time to Reevaluate the 95% Inclusion Criteria for Defining Reference Intervals?
    El-Khoury, Joe M.
    Badrick, Tony
    Theodorsson, Elvar
    CLINICAL CHEMISTRY, 2024, 70 (05) : 700 - 702
  • [36] A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials
    Sajobi, Tolulope T.
    Li, Guowei
    Awosoga, Oluwagbohunmi
    Wang, Meng
    Menon, Bijoy K.
    Hill, Michael D.
    Thabane, Lehana
    SYSTEMATIC REVIEWS, 2018, 7
  • [37] A comparison of meta-analytic methods for synthesizing evidence from explanatory and pragmatic trials
    Tolulope T. Sajobi
    Guowei Li
    Oluwagbohunmi Awosoga
    Meng Wang
    Bijoy K. Menon
    Michael D. Hill
    Lehana Thabane
    Systematic Reviews, 7
  • [38] On synthesis evidence from explanatory and pragmatic trials: a comparison of meta-analytic methods
    Sajobi, Tolulope
    Awosoga, Oluwagbohunmi
    Wang, Meng
    Brobbey, Anita
    Li, Guowei
    Menon, Bijoy K.
    Hill, Michael D.
    Thabane, Lehana
    TRIALS, 2017, 18
  • [39] Systematic review of intervention design and delivery in pragmatic and explanatory surgical randomized clinical trials
    Blencowe, N. S.
    Boddy, A. P.
    Harris, A.
    Hanna, T.
    Whiting, P.
    Cook, J. A.
    Blazeby, J. M.
    BRITISH JOURNAL OF SURGERY, 2015, 102 (09) : 1037 - 1047
  • [40] HOW PRAGMATIC ARE PRAGMATIC RANDOMIZED CONTROL TRIALS IN ONCOLOGY? A SYSTEMATIC REVIEW
    Young, Sympascho
    Phaterpekar, Kiran
    Jayatilaka, Aruni
    Boldt, Gabriel
    Palma, David
    Bauman, Glenn
    RADIOTHERAPY AND ONCOLOGY, 2024, 198 : S7 - S7